The TMJ disorders market is gaining attention as rising cases of temporomandibular disorders and advancements in treatment continue to shape industry growth. According to Straits Research, the global TMJ disorders market size was valued at USD 588.34 Million in 2024 and is projected to grow from USD 614.11 Million in 2025 to USD 865.33 Million by 2033, registering a CAGR of 4.38% during the forecast period (2025–2033).
Temporomandibular disorders (TMD) affect the jaw joint and surrounding muscles, often leading to jaw pain, earaches, headaches, and difficulty in jaw movement. According to the American Family Physician, up to 15% of people suffer from TMD, with the condition most common between ages 20 and 40.
Market Growth Factors
Increasing Prevalence of TMJ Disorders
According to Straits Research, the prevalence of TMJ disorders is estimated between 5% and 12%, and women are more affected than men, particularly those aged 20 to 40. Research studies, including one conducted in North Saudi Arabia among university students, reveal high prevalence rates linked with habits like nail-biting, clenching, and mouth breathing, further driving market growth.
Technological Advancements in Treatment
Innovations in tissue engineering, 3D printing, and patient-specific jaw joint replacements have improved diagnosis and treatment. For example, AIIMS introduced a customized artificial jaw-joint replacement in 2020 using 3D printing technology. Such advancements are propelling the demand for effective TMJ treatments.
Market Restraining Factor
Poorly Understood Etiology
Despite its prevalence, only about 2% of people with TMJ-related symptoms seek treatment. According to Straits Research, unclear etiology and underdiagnosis limit proper management, which in turn hampers market growth.
Market Opportunity
Rising Demand for Non-Invasive Treatments
Pharmacotherapy, particularly NSAIDs and benzodiazepines, continues to dominate demand due to their pain-relieving benefits. According to Straits Research, the rising preference for these non-invasive treatment modalities creates strong opportunities for drug manufacturers and healthcare providers.
Regional Insights
- Americas hold the largest market share, growing at a CAGR of 4.32%, supported by high disease prevalence and adoption of advanced treatments.
- Europe is expanding at a CAGR of 3.91%, driven by high healthcare expenditure and advanced medical infrastructure.
- Asia-Pacific is anticipated to register the fastest growth, supported by government healthcare initiatives, increasing prevalence of TMD, and higher disposable incomes.
- Middle East and Africa are witnessing steady growth due to rising healthcare funding and infrastructure investments, especially in Saudi Arabia.
Type Insights
The myofascial pain segment dominates the market, with a CAGR of 4.15%, as it affects up to 85% of the global population. Osteoarthritis of the TMJ also accounts for a significant share, with CBCT emerging as an effective diagnostic tool.
Treatment Insights
The medication segment holds the largest share, with a CAGR of 4.46%, as pain relievers, anti-inflammatories, antidepressants, and muscle relaxants remain widely used. Non-drug therapies, including oral splints, physical therapy, and counseling, are also gaining traction.
End-User Insights
Hospitals and clinics dominate the market, projected to grow at a CAGR of 4.45%, due to high patient volumes. Ambulatory surgery centers are also emerging rapidly due to cost-effective and less stressful treatment environments.
Key Players
According to Straits Research, leading companies in the TMJ disorders market include:
- Novartis AG
- Mylan NV
- Allergan
- Teva Pharmaceutical Industries Ltd
- Abbott Laboratories
- Sun Pharmaceutical Industries Limited
- Bristol-Myers Squibb Company
- Bayer AG
- Zydus Cadila
- Jubilant Life
Recent Developments
December 2022 – Novartis AG shared Phase III APPLY-PNH trial results showing significant benefits of iptacopan in patients compared to standard anti-C5 therapy.
Market Segmentations
- By Type: Myofascial Pain, Internal Derangement, Osteoarthritis
- By Treatment: Medication, Therapies, Surgical, Others
- By End-User: Hospitals and Clinics, Ambulatory Surgery Centers, Academic Institutes, Research Institutes, Others
- By Region: North America, Europe, Asia-Pacific, Middle East and Africa, LATAM
About Us
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.
Contact Us
Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/
